Vancouver, Canada, March  27, 2026  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (&#34;Clearmind&#34; or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel,

CMND

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Expands Patent Portfolio with New Therapeutic Innovations

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (&amp;#34;Clearmind&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biotech company focused on the discovery and development of novel,
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Clearmind Medicine has filed a patent application in India for next-generation psychedelic compounds targeting mental health issues and addiction. This enhances its intellectual property portfolio, potentially positioning the company to deliver safer and scalable treatment options in a growing market.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Clearmind filed an Indian patent for psychedelic-based mental health compounds.</li><li>New compounds aim to provide scalable treatments for mental health disorders.</li><li>Company&#039;s portfolio now includes 19 patent families and 31 granted patents.</li><li>The patent reinforces Clearmind&#039;s exclusive agreement with Yissum Research.</li><li>Innovative compounds may overcome traditional psychedelic limitations.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Yissum Research Development Company (N/A): Exclusive licensing agreement with Clearmind enhances research capabilities.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This update falls under Corporate Developments as Clearmind expands its intellectual property, suggesting a robust strategy for growth in the emerging psychedelic therapeutic market.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Pending patents could drive CMND stock price if approvals are secured.</li><li>Increased interest in psychedelic therapies may boost investor confidence in CMND.</li><li>Strategic partnerships with research institutions can expand CMND&#039;s market presence.</li><li>Potential market for mental health treatments estimated to grow significantly.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Clearmind&#039;s patent application strengthens its IP portfolio.</li><li>The portfolio consists of 19 patent families and 31 granted patents.</li><li>Compounds aim to address under-treated health problems.</li><li>Company collaborates with Yissum Research of the Hebrew University.</li><li>Innovative compounds are designed to be non-hallucinogenic.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Invest in CMND for potential growth driven by innovation in mental health treatments within 12 months.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CMND">CMND</a>) ("Clearmind" or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction. The patent application, filed with the Indian Patent Office, forms part of the Company's expanding global intellectual property portfolio and builds upon its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. It protects novel new compounds designed to overcome the limitations of classical psychedelics, offering potentially safer, more effective, and scalable treatment options for underserved mental health conditions and addictive disorders. About Clearmind Medicine Inc. Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The Company's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND.&#34; For further information, visit: <a href="https://www.globenewswire.com/Tracker?data=60MFVnMKEoEfkbS3OmXVBBwrhbpR3ZEMjMDnAoprsY4QtMc3HoMOOL-MpRihkVpW1SWGmp8fVTXSiPpzqAaraE8e_7esURMgU5mso60mjP0En3LLzjYcK_CywEu3iFbu" target="_blank">https://www.clearmindmedicine.com</a> or contact: Investor Relations <a href="https://www.globenewswire.com/Tracker?data=qesPqGkQuJPxZqStdaa1WASAQ2s1ZR-VKzUb7_IBOEa8g-pxN5K7-8vndgxMfmLA9fA5tOS_yVBozDr3dhRqEuW8D131Oe8jDF4cjCHNqwxdQaTWlwqf0kqbzFg9xuNK" target="_blank">invest@clearmindmedicine.com</a> <a href="https://www.globenewswire.com/Tracker?data=Xr37TV64PNyScMRAyiSudNEelWKmv_jdzem1ld3-DtWdKY4jeaZ6Ro9BhoGza-VWtEMwWNB1hj-fy-9Is_kStv5FtX83dj8TnzGAXemaPHmZIpfkzAqek3cTSdD-PAh5" target="_blank">www.Clearmindmedicine.com</a> Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expanding global intellectual property portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTY4NSM3NTA2OTkwIzUwMDA4NjkzNA=="></img> <img alt="" src="https://ml.globenewswire.com/media/M2IwYzY3OGEtM2IwYi00NzExLWI5ODUtZmI5NGIxM2NlNDBhLTUwMDA4NjkzNC0yMDI2LTAzLTI3LWVu/tiny/Clearmind-Medicine-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bd17cbf4-8124-4f86-8a4c-1fafbb6785af"><img src="https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg" border="0" width="150" height="23" alt="Primary Logo"></img></a>

Clearmind Medicine has filed a patent application in India for next-generation psychedelic compounds targeting mental health issues and addiction. This enhances its intellectual property portfolio, potentially positioning the company to deliver safer and scalable treatment options in a growing market.

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News